SCHEMBL3343545

SCHEMBL3343545

O=C(O)CCc1cc(Cl)c(-c2noc(-c3cn4ccccc4n3)n2)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
HPGD P15428 4/20 0.41
CYP3A4 P08684 1/20 0.41
KDM4E B2RXH2 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 3/20 0.38
RAB9A P51151 2/20 0.38
POLB P06746 1/20 0.38
GFER P55789 1/20 0.38
S1PR1 P21453 8/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 2/20 0.38
NPC1 O15118 2/20 0.38
MEN1 O00255 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 3/20 0.37
FFAR1 O14842 1/20 0.37
GAA P10253 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340196 0.89 S1PR1 (0.38) S1PR1FFAR1CNR1CNR2
SCHEMBL3340688 0.88 S1PR1 (0.38) ALDH1A1HPGDCYP3A4LMNAS1PR1
SCHEMBL3347312 0.85 CNR2 (0.42) ALDH1A1HPGDKDM4ESMN1; SMN2RAB9A
SCHEMBL3340962 0.82 S1PR1 (0.43) ALDH1A1HPGDS1PR1KMT2AMEN1
SCHEMBL3339929 0.82 S1PR1 (0.37) S1PR1FFAR1CNR1CNR2
SCHEMBL3339335 0.80 S1PR1 (0.38) S1PR1FFAR1
SCHEMBL2499500 0.80 S1PR1 (0.36) S1PR1FFAR1
SCHEMBL3338104 0.80 S1PR1 (0.38) S1PR1FFAR1
SCHEMBL3340921 0.80 S1PR1 (0.38) S1PR1FFAR1
SCHEMBL3340589 0.80 S1PR1 (0.38) S1PR1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 ALDH1A1 1246/4885HPGD 1638/4885CYP3A4 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.